A Randomized, Double-Blinded, Placebo-Controlled Trial of Homeopathy in Acute Viral Tonsillitis in Children.

J Integr Complement MedApr 10, 2026 (epub)
Clinical ResearchPediatrics

Sourav De, Shubhamoy Ghosh, Satadal Das et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-centre, double-blind, randomized, placebo-controlled trial evaluated individualized homeopathic medicines (IHMs), added to supportive care, in 78 children with acute viral tonsillitis. Compared with placebo, IHMs produced a greater reduction in Tonsillopharyngitis assessment scores by day 3 (adjusted mean difference -2.01, 95% confidence interval -2.78 to -1.24; p < 0.001). Meaningful recovery at day 3 occurred in 88.5% vs. 38.5%, and median time to sore throat remission and complete clinical recovery was 3.0 vs. 4.8 days. The authors report that results were robust across sensitivity and multiplicity-adjusted analyses.

Key findings

  • At day 3, the adjusted mean difference in Tonsillopharyngitis assessment score was -2.01 (95% confidence interval -2.78 to -1.24; p < 0.001) in favour of IHMs.
  • Meaningful recovery at day 3 was reported in 88.5% with IHMs vs. 38.5% with placebo; the reported number needed to treat was 2.0.
  • Median time to sore throat remission and complete clinical recovery was 3.0 vs. 4.8 days; both comparisons had p < 0.001.

Why it matters

The trial reports improvements in an objective tonsillopharyngitis score and recovery outcomes when individualized homeopathic medicines were added to supportive care. These findings may be relevant to discussions of adjunctive approaches for childhood acute viral tonsillitis, while interpretation should account for the single-centre setting and the need for evidence beyond this trial.

What to keep in mind

The trial was conducted in a single-centre outpatient pediatric setting and enrolled 78 children, limiting the breadth of the evidence.

Source

Published in J Integr Complement Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.